Although I'm a big fan of this company, I do have some concerns about the revenue projections that we've been seeing from e.g. 51 Capital, which seem to be based on PAR charging between $1k and $2k per course of six injections. I don't believe that to be a realistic prospect given that Elmiron (same drug, but in capsule format) is available so much more cheaply (I paid a non-subsidised $50 for 30 capsules at my local pharmacy, and branded versions of Elmiron (made here in Australia by Arthropharm), or a generic (made in India by Swati Pharma), are both freely available for online ordering at relatively low prices.
I seriously doubt that the TGA in Australia, or e.g the NHS in the UK, would be willing to pay PAR such super-profits on a repurposed drug like PPS. While there may be some demand for privately prescribed (non-subsidised) supply, for this to take off it needs to carry a government subsidy that will bring the price down to the standard Australian prescription charge of around $35 per course, and given the potentially huge demand, I don't think there's any way that the Australian government, or governments anywhere, will be looking at providing the level of subsidy that seems to be baked into some of the revenue projections we've been seeing here and elsewhere.
PAR Price at posting:
$1.50 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)